Your browser doesn't support javascript.
loading
Endometrial carcinosarcoma.
Bogani, Giorgio; Ray-Coquard, Isabelle; Concin, Nicole; Ngoi, Natalie Yan Li; Morice, Philippe; Caruso, Giuseppe; Enomoto, Takayuki; Takehara, Kazuhiro; Denys, Hannelore; Lorusso, Domenica; Coleman, Robert; Vaughan, Michelle M; Takano, Masashi; Provencher, Diane Michele; Sagae, Satoru; Wimberger, Pauline; Póka, Robert; Segev, Yakir; Kim, Se Ik; Kim, Jae-Weon; Candido Dos Reis, Francisco Jose; Ramirez, Pedro T; Mariani, Andrea; Leitao, Mario; Makker, Vicky; Abu-Rustum, Nadeem R; Vergote, Ignace; Zannoni, Gianfranco; Tan, David; McCormack, Mary; Paolini, Biagio; Bini, Marta; Raspagliesi, Francesco; Benedetti Panici, Pierluigi; Di Donato, Violante; Muzii, Ludovico; Colombo, Nicoletta; Pignata, Sandro; Scambia, Giovanni; Monk, Bradley J.
Afiliación
  • Bogani G; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy giorgiobogani@yahoo.it.
  • Ray-Coquard I; Centre Leon Berard, LYON CEDEX 08, Centre, France.
  • Concin N; Department of Gynecology and Obstetrics; Innsbruck Medical Univeristy, Innsbruck, Austria.
  • Ngoi NYL; National University Cancer Institute, Singapore.
  • Morice P; Department of Surgery, Institut Gustave RoussT, Villejuif, France.
  • Caruso G; Department of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Rome, Italy.
  • Enomoto T; Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Belgium.
  • Takehara K; Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
  • Denys H; Department of Medical Oncology, University Hospital Ghent, Gent, Belgium.
  • Lorusso D; Policlinico Gemelli, Rome, Italy.
  • Coleman R; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Vaughan MM; Department of Medical Oncology, Canterbury Regional Cancer and Haematology Service, Christchurch, New Zealand.
  • Takano M; Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Medical, Japan.
  • Provencher DM; Centre Hospitalier de LUniversite de Montreal, Montreal, Québec, Canada.
  • Sagae S; Hokkaido Ohno Memorial Hospital, Sapporo, Japan.
  • Wimberger P; Department of Gynecology and Obstetrics, Technische Universitat Dresden Medizinische Fakultat Carl Gustav Carus, Dresden, Germany.
  • Póka R; University of Debrecen, Debrecen, Hungary.
  • Segev Y; Department of Obstetrics and Gynecology, Carmel Hospital, Haifa, Israel.
  • Kim SI; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea.
  • Kim JW; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea.
  • Candido Dos Reis FJ; Ginecologia e Obstetricia, Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto, Ribeirao Preto, Brazil.
  • Ramirez PT; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Mariani A; Department of Gynecologic Surgery, Mayo Clinic Rochester, Rochester, Minnesota, USA.
  • Leitao M; Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
  • Makker V; Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
  • Abu-Rustum NR; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
  • Vergote I; Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium.
  • Zannoni G; Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Tan D; National University Cancer Institute, Singapore.
  • McCormack M; Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Paolini B; Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
  • Bini M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy.
  • Raspagliesi F; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy.
  • Benedetti Panici P; Department of Obstetrics and Gynecology, University Sapienza of Roma, Rome, Italy.
  • Di Donato V; Department of Obstetrics and Gynecology, University Sapienza of Roma, Rome, Italy.
  • Muzii L; Department of Maternal, Infantile, and Urological Sciences, Umberto I Hospital, Sapienza University of Rome, Roma, Italy.
  • Colombo N; Medical Gynecologic Oncology Unit; University of Milan Bicocca; Milan; Italy, European Institute of Oncology, Milano, Italy.
  • Pignata S; Department of Gynaecological Oncology, National Cancer Institute Napels, Naples, Italy.
  • Scambia G; Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
  • Monk BJ; HonorHealth, University of Arizona, Creighton University, Phoenix, Arizona, USA.
Int J Gynecol Cancer ; 33(2): 147-174, 2023 02 06.
Article en En | MEDLINE | ID: mdl-36585027
Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation (conversion theory). The clinical presentation and diagnostic work-up roughly align with those of the more common endometrioid counterpart, although endometrial carcinosarcoma is more frequently diagnosed at an advanced stage. Endometrial carcinosarcoma is not a single entity but encompasses different histological subtypes, depending on the type of carcinomatous and sarcomatous elements. The majority of endometrial carcinosarcomas are characterized by p53 abnormalities. The proportion of POLE and microsatellite instablity-high (MSI-H) is directly related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.The management of non-metastatic disease is based on a multimodal approach with optimal surgery followed by (concomitant or sequential) chemotherapy and radiotherapy, even for early stages. Palliative chemotherapy is recommended in the metastatic or recurrent setting, with carboplatin/paclitaxel doublet being the first-line regimen. Although the introduction of immunotherapy plus/minus a tyrosine kinase inhibitor shifted the paradigm of treatment of patients with recurrent endometrial cancer, patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or the combination. However, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the use of pembrolizumab and lenvatinib in endometrial cancer (all histotypes) after progression on chemotherapy and single-agent immunotherapy in MSI-H cancers. In the era of precision medicine, emerging knowledge on molecular endometrial carcinosarcoma is opening new promising therapeutic options for more personalized treatment. The present review outlines state-of-the-art knowledge and future directions for patients with endometrial carcinosarcoma.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Uterinas / Carcinosarcoma / Neoplasias Endometriales Límite: Female / Humans Idioma: En Revista: Int J Gynecol Cancer Asunto de la revista: GINECOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Uterinas / Carcinosarcoma / Neoplasias Endometriales Límite: Female / Humans Idioma: En Revista: Int J Gynecol Cancer Asunto de la revista: GINECOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido